Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) Research & Development (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Research & Development for 15 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 34.54% to $2.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.4 million through Dec 2025, down 20.8% year-over-year, with the annual reading at $8.4 million for FY2025, 20.8% down from the prior year.
  • Research & Development for Q4 2025 was $2.9 million at Plus Therapeutics, up from $2.4 million in the prior quarter.
  • The five-year high for Research & Development was $3.0 million in Q1 2023, with the low at $75000.0 in Q4 2023.
  • Average Research & Development over 5 years is $2.1 million, with a median of $2.2 million recorded in 2024.
  • The sharpest move saw Research & Development tumbled 96.49% in 2023, then soared 2814.67% in 2024.
  • Over 5 years, Research & Development stood at $1.5 million in 2021, then surged by 43.39% to $2.1 million in 2022, then crashed by 96.49% to $75000.0 in 2023, then skyrocketed by 2814.67% to $2.2 million in 2024, then surged by 34.54% to $2.9 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $2.9 million, $2.4 million, and $1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.